Continuing our cytokine series, we now switch horses from a creative new therapeutic utilising red blood cells that Rubius Therapeutics are pioneering to a very different technology involving synthetic amino acids, in what is known as a ‘Not Alpha’ IL–2 approach from Synthorx.
We have covered new developments in IL–2 based cytokines from Roche and Nektar previously, so what’s cool about the alternative early development that is THOR–707?
To find out, we conducted an expert interview with Synthorx’s Dr Laura Shawver and learned some fascinating details about their novel platform that is sending new molecules into the clinic in the very near future.
To learn more and get a heads up on our latest oncology insights and thought leader interviews, subscribers can log-in or you can click to gain access to BSB Premium Content.
After writing about how the design aspects of antibodies can affect clinical performance recently, a few fascinated readers wrote in asking if there were more examples they could learn from.
Sure there are, and so that simple question inspired five more examples.
They range from small to large biotech/pharma, both public and private – no one has dominance in innovation chops, after all.
In this latest review we look at examples from CAR-T cell therapies, antibodies, immunocytokines and even bispecifics – there’s a lot of cool science going under the hood that many casual observers simply do not realise.
What’s more, some of the selected improvements and changes may (or may not) lead to enhancement of clinical performance down the road, so it is important to pay attention to what’s going on relative to each niche rather than be surprised and caught unaware…
To learn more and get a heads up on our latest oncology insights and R&D analysis, subscribers can log-in or you can click to gain access to BSB Premium Content.